Endocrinology

  • SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation
    Enrico G. Ferro, MD, Bertram Pitt, MD and Deepak L. Bhatt, MD, MPH
    Cleveland Clinic Journal of Medicine November 2021, 88 (11) 601-606; DOI: https://doi.org/10.3949/ccjm.88a.21045

    SGLT-2 inhibitors remain vastly underused in clinical practice despite their broad cardiorenal benefits.

  • DXA and clinical challenges of fracture risk assessment in primary care
    Susan Williams, MS, RD, MD, CCD, FACP, FACE, Leila Khan, MD and Angelo A. Licata, MD, PhD, FACP, FACE
    Cleveland Clinic Journal of Medicine November 2021, 88 (11) 615-622; DOI: https://doi.org/10.3949/ccjm.88a.20199

    Overdependence on dual-energy x-ray absorptiometry, especially for patient populations the test was not designed for, may lead to poor clinical decisions.

  • Elevated hCG can be a benign finding in perimenopausal and postmenopausal women
    Lea El Hage, MD and Betul Hatipoglu, MD
    Cleveland Clinic Journal of Medicine November 2021, 88 (11) 635-639; DOI: https://doi.org/10.3949/ccjm.88a.18069

    A search for the source of the elevation in perimenopausal and postmenopausal women who are not pregnant and have no disease or tumor may delay patient care.

  • Ketogenic diets in the management of type 1 diabetes: Safe or safety concern?
    Lauren Anne Buehler, MD, MPH, Dawn Noe, RDN, LD, CDCES, Shannon Knapp, BSN, RN, CDCES, Diana Isaacs, Pharm D, CDCES and Kevin M. Pantalone, DO, ECNU, FACE
    Cleveland Clinic Journal of Medicine October 2021, 88 (10) 547-555; DOI: https://doi.org/10.3949/ccjm.88a.20121

    A review of the potential risks and benefits for managing type 1 diabetes based on available evidence.

  • Leriche syndrome
    Hiroki Matsuura, MD and Hiroyuki Honda, MD, PhD
    Cleveland Clinic Journal of Medicine September 2021, 88 (9) 482-483; DOI: https://doi.org/10.3949/ccjm.88a.20179

    Physical examination revealed pallor of the toes, cold extremities, dry skin, and absence of bilateral femoral pulses. The patient also disclosed erectile dysfunction.

  • Teriparatide: Label changes and identifying patients for long-term use
    Paul D. Miller, MD, HDSc (HON), E. Michael Lewiecki, MD, Kelly Krohn, MD and Elliott Schwartz, MD
    Cleveland Clinic Journal of Medicine September 2021, 88 (9) 489-493; DOI: https://doi.org/10.3949/ccjm.88a.21011

    The changes leave clinicians with the challenge of identifying appropriate patients.

  • Autoimmune brain disease: Think before testing
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 420-421; DOI: https://doi.org/10.3949/ccjm.88b.08021

    Immune serologic tests are not specific for any defined clinical diagnosis and thus should not be used to drive therapeutic decisions.

  • How do you effectively evaluate the elderly for alcohol use disorder?
    Moronkeji Fagbemi, MD, FASAM
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 434-439; DOI: https://doi.org/10.3949/ccjm.88a.20123

    A brief review of clues to an underrecognized and underdiagnosed problem with physical as well as emotional and social consequences.

  • Antiobesity drug therapy: An individualized and comprehensive approach
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta R. Kashyap, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 440-448; DOI: https://doi.org/10.3949/ccjm.88a.20080

    As part of a comprehensive plan, these drugs can provide lasting obesity control and additional health benefits, including decreased cardiovascular risk.

  • The obesity paradox in heart failure: What is the role of cardiorespiratory fitness?
    Asad Khan, MD, Erik H. Van Iterson, PhD and Luke J. Laffin, MD
    Cleveland Clinic Journal of Medicine August 2021, 88 (8) 449-458; DOI: https://doi.org/10.3949/ccjm.88a.20098

    What should these patients be advised about weight management and about cardiorespiratory fitness, a major factor influencing the paradox?

Pages